ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1643

Psa Impact of Disease Questionnaire Scores Are Correlated with Disease Activity, As Measured By Cdapsa in Patients with Psa

Ana-Maria Orbai1, Klaus Krüger2, Frank Behrens3, Uta Kiltz4, Benoit Guerette5, Lillian Mellars5, Michele Brunori5 and Jürgen Wollenhaupt6, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Medical Centre of Rheumatology, Munich, Germany, 3Clinical Research Rheumatology and Fraunhofer Institute IMETranslation, Goethe University, Frankfurt, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Celgene Corporation, Summit, NJ, 6Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, patient outcomes, Patient questionnaires, psoriatic arthritis and quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: We examined clinical correlations between disease activity, as measured with the Clinical Disease Activity for PsA (cDAPSA) components and PsA life impact/health-related quality of life (HRQoL) assessed with the PsA Impact of Disease Questionnaire (PsAID12). We hypothesized that PsAID12 scores will be statistically different among the disease activity categories and there will be moderate correlation between PsAID12 and cDAPSA.

Methods: LAPIS-PsA is a multicenter, prospective, non-interventional study assessing long-term apremilast (APR) treatment in adult patients with active PsA in routine clinical practice in Germany. Analyses were performed in patients treated with APR 30 mg BID who had cDAPSA and PsAID12 scores at baseline (BL). We also report data from Visits 1 to 3 (V1: ≥1 month; V2: ≥4 months; V3: ≥7 months). Mean PsAID12 scores and proportions of patients meeting the PsAID12 Patient-Acceptable Symptom State (PASS), defined as PsAID12 of 4, were assessed among each cDAPSA category at BL. PsAID12 scores were compared among the cDAPSA categories at BL and each visit using the ANOVA method. Pearson correlations were calculated between cDAPSA and PsAID12 at BL, V1, V2, and V3.

Results: A total of 330 patients were included in the analysis population. At BL, patients had a mean PsAID12 of 5.4 and a mean cDAPSA of 28.6. Mean PsAID12 and cDAPSA scores are reported at all visits (Table). Patients reported incrementally reduced mean cDAPSA and consistent improvements in PsAID12 scores from BL to V3. Patients with low disease activity (cDAPSA >4−≤13) at BL had a mean (SD) PsAID12 score of 3.2 (1.5) with 74% in PsAID12 PASS (Figure). Those with moderate (cDAPSA >13−≤27) and high (cDAPSA >27) disease activity had mean (SD) PsAID12 scores of 5.0 (2.0) and 6.1 (1.7), with 33% and 11% showing PsAID12 PASS, respectively. Consequently, proportions of patients achieving PsAID12 PASS decreased with higher disease activity (Figure). At BL and V1-3, PsAID12 scores were significantly different among the cDAPSA categories (P<0.001). Additionally, significant moderate to high correlations were observed between cDAPSA and PsAID12 at V1 (Pearson’s coefficient r=0.41; P<0.0001), V2 (r=0.64; P<0.0001), and V3 (r=0.70; P<0.0001).

Conclusion: Results from this observational PsA study of APR demonstrate a significant correlation between disease activity, as assessed by cDAPSA, and PsA-specific life impact/HRQoL, as measured by PsAID12. More patients met the PsAID12 PASS cutoff at lower disease activity levels, suggesting that improvements in PsA disease activity lead to decreased impact of disease.


Disclosure: A. M. Orbai, Abbvie, Celgene, Eli Lilly and Company, Horizon, Janssen, Novartis, Pfizer, 2,Eli Lilly and Company, Janssen, Novartis, Pfizer, UCB, 5; K. Krüger, MSD Sharp Dohme GmbH, 9,AbbVie Inc., 9,BMS, 9,Celgene Corporation, 9,Janssen, 9,Lilly, 9,Pfizer, Inc., 9,Sanofi-Aventis, 9,UCB, Inc., 9; F. Behrens, Abbvie, Pfizer, Roche, Chugai, Prophylix, Novartis, Iron4U, 2; U. Kiltz, AbbVie Inc., 2, 5,Chugai, 2, 5,Eli Lilly and Co., 2, 5,Grunenthal, 2, 5,Janssen, 2, 5,MSD, 2, 5,Novartis, 2, 5,Pfizer, Inc., 2, 5,Roche, 2, 5,UCB, Inc., 2, 5; B. Guerette, Celgene Corporation, 3; L. Mellars, Celgene Corporation, 3; M. Brunori, Celgene Corporation, 3; J. Wollenhaupt, Celgene Corporation, 2.

To cite this abstract in AMA style:

Orbai AM, Krüger K, Behrens F, Kiltz U, Guerette B, Mellars L, Brunori M, Wollenhaupt J. Psa Impact of Disease Questionnaire Scores Are Correlated with Disease Activity, As Measured By Cdapsa in Patients with Psa [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/psa-impact-of-disease-questionnaire-scores-are-correlated-with-disease-activity-as-measured-by-cdapsa-in-patients-with-psa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/psa-impact-of-disease-questionnaire-scores-are-correlated-with-disease-activity-as-measured-by-cdapsa-in-patients-with-psa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology